Sandbox:Mitra3
| Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reperfusion | Maintenance of RV preload | Decreased RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:<be>
| • Systemic or pulmonary vasodilators: *Inhaled nitric oxide | • In patients with bradyarrhthmias: Atropine Pacemaker | In patients with refractory hypotension | May be needed in patients with cardiogenic shock secondary to RVMI | {{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||